Antiviral re-treatment of IFN-Ribavirin non-responders for recurrent post-transplantation hepatitis C

Clinical Transplantation

Volumn 25, Issue 1, 2011, Pages 131-135

  Yedibela, Süleyman ^a   Demir, Resit ^a   Melling, Nathaniel ^a   Aydin, Ünal ^b   Schuppan, Detlef ^c   Müller, Volker ^a   Hohenberger, Werner ^a   Schönleben, Frank ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b GAZIANTEP UNIVERSITY   (Turkey)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Hepatitis C recurrence; Liver transplantation; Non responder; Pegylated interferon; Relapser

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; PEGINTERFERON; PREDNISOLONE; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN; TACROLIMUS; THYMOCYTE ANTIBODY; VIRUS RNA;

ADULT; AGED; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; BLOOD TRANSFUSION; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER HISTOLOGY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; RECURRENT INFECTION; THROMBOCYTOPENIA;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON ALFA-2B; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RECURRENCE; RETREATMENT; RIBAVIRIN; RNA, VIRAL; SURVIVAL RATE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 79551700563     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2009.01201.x     Document Type: Article

References (28)

1. Berenguer M, Lope-Labrador FX, Wright TL. Hepatitis C and liver transplantation. J Hepatol 2001: 35: 666.
2. Forns X, Garcia-Retortillo M, Serrano T et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003: 39: 389.
3. Berenguer M, Prieto M, Rayon JM et al. Natural history of clinically compensated HCV-related graft cirrhosis following liver transplantation. Hepatology 2000: 32: 852.
4. Bahr MJ, Manns MP. Changing faces - natural course and treatment of hepatitis C after liver transplantation. J Hepatol 2004: 40: 699.
5. Wang CS, Ko HH, Yoshida EM, Marra CA, Richardson K. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant 2006: 6: 1586.
6. Texeira R, Pastacaldi S, Papatheodoridis GV, Burroughs AK. Recurrent hepatitis C after liver transplantation. J Med Virol 2000: 61: 443.
7. Gane E, Portmann BC, Naoumov NV et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996: 334: 815.
8. Charlton M, Seaberg E, Wiesner R et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998: 28: 823.
9. Charlton M. Hepatitis C infection in liver transplantation. Am J Transplant 2001: 1: 197.
10. Ferenci P, Formann E, Laferl H et al. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment naïve patients with chronic hepatitis C genotype 1 infection. J Hepatol 2006: 44: 275.
11. Thuluvath PJ, Maheshwari A, Mehdi J et al. Randomised, double-blind, placebo controlled trials of interferon, ribavirin, and amantadine versus interferon, ribavirin, and placebo in treatment naïve patients with chronic hepatitis C. Gut 2004: 53: 130.
12. Sherman M, Yoshida EM, Deschenes M et al. Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. Gut 2006: 55: 1631.
13. Hasan F, Al-Khaldi J, Asker H et al. Peginterferon alpha-2b plus ribavirin with or without amantadine for the treatment of non-responders to standard interferon and ribavirin. Antivir Ther 2004: 9: 499.
14. Yedibela S, Schuppan D, Müller V et al. Successful treatment of hepatitis C reinfection with interferon-α2b and ribavirin after liver transplantation - A long-term follow-up. Liver Int 2005: 25: 717.
15. Heintges T, Wands JR. Hepatitis C virus: epidemiology and transmission. Hepatology 1997: 26: 521.
16. Rodriguez-Luna H, Vargas HE. Management of hepatitis C virus infection in the setting of liver transplantation. Liver Transl 2005: 11: 479.
17. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003: 9: 331.
18. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001: 345: 41.
19. Everhart JE, Wei Y, Eng H et al. Recurrent and new hepatitis C virus infection after liver transplantation. Hepatology 1999: 29: 1220.
20. Kim WR, Brown RS Jr, Terrault NA, El-Sareg H. Burden of liver disease in the United States: summary of a workshop. Hepatology 2002: 36: 227.
21. Firpi RJ, Abdelmalek MF, Soldevila-Pico C et al. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transpl 2002: 8: 1000.
22. Nair S, Khan S, Loss G et al. Treatment of recurrent hepatitis C in liver transplant recipients: is there any histological benefit? Liver Transpl 2003: 9: 354.
23. Mukherjee S, Lyden E, Mccashland TM, Schafer DF. Interferon alpha 2b and ribavirin for the treatment of recurrent hepatitis C after liver transplantation: cohort study of 38 patients. J Gastroenterol Hepatol 2005: 20: 198.
24. Fernandez I, Meneu JC, Colina F et al. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation. Liver Transpl 2006: 12: 1805.
25. Mukherjee S, Lyden E. Impact of pegylated interferon a-2B and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: an open-label series. Liver Int 2006: 26: 529.
26. Picciotto FP, Tritto G, Lanza AG et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol 2007: 46: 459.
27. Bizollon T, Adham M, Pradat P et al. Triple antiviral therapy with amantadine for IFN-Ribavirin nonresponders with recurrent posttransplantation hepatitis C. Transplantation 2005: 79: 325.
28. Smallwood GA, Davis L, Connor K, Martinez E, Stieber AC, Heffron TG. Nonresponders of interferon/ribavirin treatment for recurrent hepatitis C following liver transplantation. Transpl Proc 2003: 35: 1476.